7Baggers

Lightbridge Quarterly Balance Sheets Chart

Quarterly
 | 
Annual
 
 Cash and Cash Eq  
 Deferred Revenue  
20100630 20101231 20110630 20191231 20200331 20200630 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20241231 05.7111.4317.1422.8528.5634.2839.99Milllion

Lightbridge Quarterly Balance Sheets Table

Quarterly
 | 
Annual
 
Unit: USD2024-12-31 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-06-30 2020-03-31 2019-12-31 2011-06-30 2010-12-31 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-03-31 2008-12-31 2008-06-30 2008-03-31 
                             
  assets                           
  current assets                           
  cash and cash equivalents39,990,827 27,942,421 28,598,445 29,235,892 28,204,016 28,051,303 28,899,997 31,284,501 29,268,074 28,226,863 24,747,613 16,133,652 13,855,982 15,236,151 17,056,313 16,334,353 17,958,989 1,294,332 3,569,526 3,077,451 2,000,134  3,872,046 4,375,361 10,360,068 5,185,597 4,705,577 
  prepaid expenses and other current assets324,378 401,859 207,063 252,403 355,619 393,437 115,264 305,919 409,339 558,777 113,452 247,211 389,461 637,651 254,652 344,652 47,371           
  total current assets40,315,205 28,344,280 28,805,508 29,488,295 28,559,635 28,444,740 29,015,261 31,590,420 29,677,413 28,785,640 24,861,065 16,490,863 15,030,443 15,873,802 17,310,965 16,679,005 18,406,360 12,561,560 16,062,392 4,862,508 5,975,064  7,458,859 10,141,670 11,235,583 5,401,728 6,986,389 
  other assets                           
  prepaid project costs and other long-term assets528,805 479,625 483,000 486,375 489,750                       
  trademarks108,865 108,865 108,865 108,865 108,225 108,225 108,225 107,757 107,757 101,583 101,583 101,583 100,217 85,562              
  total assets40,952,875 28,932,770 29,397,373 30,083,535 29,157,610 28,897,965 29,468,486 31,698,177 29,785,170 28,887,223 24,962,648 16,592,446 15,130,660 15,959,364 19,067,471 18,481,912 20,204,844 13,164,015 16,551,782 5,331,853 6,428,004  7,927,391 10,600,889 13,932,635 7,462,128 7,233,978 
  liabilities and stockholders’ equity                           
  current liabilities                           
  accounts payable and accrued liabilities424,585 907,421 486,326 875,639 592,719 575,978 350,331 1,190,386 482,661 452,826 171,521 1,107,865 539,095 634,037 893,938 485,693 350,299 1,477,010 1,634,889 1,546,336 1,575,718  2,081,323 3,542,581 3,010,118 2,799,489 2,645,888 
  total current liabilities424,585 907,421 486,326 875,639 592,719 575,978 350,331 1,190,386 482,661 452,826 171,521 1,107,865 1,214,095 634,037 893,938 485,693 350,299        6,280,118 2,812,680 3,138,983 
  commitments and contingencies - note 5                           
  stockholders’ equity                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at december 31, 2024 and 2023                           
  common stock18,784 14,190 13,698 12,934 12,485 12,126 11,900 11,540 11,009 10,589 9,759 7,209 6,595 6,591 3,809 3,364 3,252 12,363 12,334 10,308 10,168  10,154 301,842 301,395 299,395 299,334 
  additional paid-in capital204,694,348 183,228,519 181,295,125 179,222,724 176,740,340 174,825,571 173,595,385 173,077,225 169,834,944 167,464,610 161,772,641 150,163,990 146,684,313 146,482,966 136,647,267 134,338,275 133,932,615           
  accumulated deficit-164,184,842 -155,217,360 -152,397,776 -150,027,762 -148,187,934 -146,515,710 -144,489,130 -142,580,974 -140,543,444 -139,040,802 -136,991,273 -134,689,948 -132,777,693 -131,167,596 -118,480,938 -116,348,832 -114,084,746    -50,407,044  -46,646,308  -39,563,035 -40,415,637  
  total stockholders’ equity40,528,290 28,025,349 28,911,047 29,207,896 28,564,891 28,321,987 29,118,155 30,507,791  28,434,397 24,791,127 15,484,581   18,173,533 17,996,219            
  total liabilities and stockholders’ equity40,952,875 28,932,770 29,397,373 30,083,535 29,157,610 28,897,965 29,468,486 31,698,177  28,887,223 24,962,648 16,592,446   19,067,471 18,481,912            
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at march 31, 2024 and december 31, 2023                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at december 31, 2023 and 2022                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at september 30, 2023 and december 31, 2022                           
  the accompanying notes are an integral part of these unaudited condensed consolidated financial statements.                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at june 30, 2023 and december 31, 2022                           
  prepaid project costs     345,000 345,000                     
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at march 31, 2023 and december 31, 2022                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at december 31, 2022 and 2021                           
  commitments and contingencies                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at september 30, 2022 and december 31, 2021                           
  liabilities and stockholders' equity                           
  stockholders' equity                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares, 0 shares issued and outstanding at june 30, 2022 and december 31, 2021                           
  total stockholders' equity        29,302,509    13,916,565 15,325,327   19,854,545 11,108,605 14,916,893 3,572,217 4,852,286  5,846,068 7,058,308 7,652,517 4,649,448 4,094,995 
  total liabilities and stockholders' equity        29,785,170    15,130,660 15,959,364   20,204,844 13,164,015 16,551,782 5,331,853 6,428,004  7,927,391 10,600,889 13,932,635 7,462,128 7,233,978 
  commitments and contingencies - note 4                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares                           
  accrued legal settlement costs            675,000               
  convertible series a preferred shares, 0 and 699,878 shares issued and outstanding at december 31, 2021 and 2020, respectively                           
  convertible series b preferred shares, 0 and 2,666,667 shares issued and outstanding at december 31, 2021 and 2020                           
  other receivables           110,000 785,000               
  preferred stock, 0.001par value, 10,000,000authorized shares                           
  convertible series a preferred shares,663,767shares and 699,878 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively           663                
  convertible series b preferred shares, 2,666,667 shares issued and outstanding at september 30, 2021 and december 31, 2020           2,667                
  convertible series a preferred shares, 683,852 shares and 699,878 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively            683               
  convertible series b preferred shares, 2,666,667 shares issued and outstanding at june 30, 2021 and december 31, 2020            2,667               
  convertible series a preferred shares, 699,878 shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively             699              
  convertible series b preferred shares, 2,666,667 shares issued and outstanding at march 31, 2021 and december 31, 2020             2,667              
  other receivable from joint venture                400,000           
  patent costs              1,756,506 1,802,907 1,798,484      241,845     
  commitments and contingencies –                           
  preferred stock, 0.001 par value, 10,000,000 authorized shares:                           
  convertible series a preferred shares, 728,816 and 757,770 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively              728             
  convertible series b preferred shares, 2,666,667 issued and outstanding at june 30, 2020 and december 31, 2019,              2,667             
  convertible series a preferred shares, 745,896 and 757,770 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively               745            
  convertible series b preferred shares, 2,666,667 issued and outstanding at march 31, 2020 and december 31, 2019,               2,667            
  total other assets                1,798,484 542,627 410,047 385,202 362,332  367,393 357,102 2,485,771 2,033,191 219,924 
  investee losses in excess of investment                           
  commitments and contingencies - note 6                           
  convertible series a preferred shares, 757,770 shares and 813,624 shares issued and outstanding at december 31, 2019 and 2018, respectively                757           
  convertible series b preferred shares, 2,666,667 shares issued and outstanding at december 31, 2019 and 2018                2,667           
  marketable securities                 8,613,011 10,429,252         
  restricted cash                 551,190 263,619 263,300 652,174  651,409 650,000    
  accounts receivable - project revenue and reimbursable project costs                 1,290,392 1,271,360 1,132,656 2,647,233  2,070,121 4,319,212    
  prepaid expenses & other current assets                 812,635 528,635 389,101 675,523  865,283 797,097 115,586 216,131 232,158 
  property, plant and equipment -net                 59,828          
  patent costs - net                 422,141 289,561 264,716 241,845   234,277 217,875 217,875  
  security deposits                 120,486 120,486 120,486 120,487  125,548 122,825 140,467 140,467 2,049 
  deferred revenue                 578,400  213,300     3,270,000   
  total liabilities                 2,055,410 1,634,889 1,759,636 1,575,718  2,081,323 3,542,581 6,280,118 2,812,680 3,138,983 
  preferred stock, 0.001 par value, 50,000,000 authorized shares, no shares issued and outstanding                           
  additional paid in capital - stock and stock equivalents                 70,098,180 68,917,377 56,539,091 54,836,265  52,996,913 49,902,488 46,744,676 44,530,174 43,156,026 
  deficit                 -59,087,438 -54,082,318 -52,410,629    -43,012,435   -39,418,507 
  common stock reserved for issuance, 19,226 shares and 6,451 shares at june 30, 2011 and december 31, 2010, respectively                 85,500          
  property plant and equipment -net                  79,343 84,143 90,608  101,139 102,117 211,281 27,209  
  liabilities and stockholders equity                           
  common stock reserved for issuance, 10,087 shares and 5,721 shares at september 30, 2010 and december 31, 2009, respectively                  69,500         
  common stock reserved for issuance, 4,204 shares and 5,721 shares at june 30, 2010 and december 31, 2009, respectively                   34,750        
  deferred stock compensation                   -601,303 -721,367  -548,941 -168,587 -409,168 -417,485 -430,278 
  common stock reserved for issuance, 135,318 and 5,721 shares at march 31, 2010 and december 31, 2009, respectively                    1,134,264       
  common stock reserved for issuance, 5,721 shares and 16,135 shares (restated for reverse stock split of 1 for 30, prior to reverse stock split was 484,055 shares) at december 31, 2009 and 2008, respectively                           
  common stock reserved for issuance, 3,869 shares and 16,135 shares (restated for reverse stock split of 1 to 30) at september 30, 2009 and december 31, 2008, respectively                      34,250     
  common stock reserved for issuance, 152,174 shares and 484,055 shares at march 31, 2009 and december 31, 2008, respectively                       35,000    
  accounts receivable - reimbursable project costs                        759,929   
  deferred project costs                          51,729 
  marketable securities - available for sale                        2,127,429 1,674,849 1,996,925 
  current portion long term debt                           
  customer deposit and other current liabilities                         13,191 493,095 
  notes payable - long term                           
  common stock reserved for issuance, 484,055 shares and 2,000,000 shares at september 30, 2008 and december 31, 2007, respectively                        114,787   
  accumulated other comprehensive income                        463,862 26,628 -101,580 
  common stock reserved for issuance, 2,127,626 shares and 2,000,000 shares at june 30, 2008 and december 31, 2007, respectively                         626,373  
  property plant and equipment –net                          27,665 
  patent costs – net                          217,875 
  preferred stock, -.001 par value, 50,000,000 authorized shares, no shares issued and outstanding                           
  common stock reserved for issuance, 2,000,000 shares at march 31, 2008 and december 31, 2007                          590,000 

We provide you with 20 years of balance sheets for Lightbridge stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Lightbridge. Explore the full financial landscape of Lightbridge stock with our expertly curated balance sheets.

The information provided in this report about Lightbridge stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.